Workflow
康龙化成(03759) - 2022 Q3 - 季度财报
PHARMARONPHARMARON(HK:03759)2022-10-27 14:36

Revenue and Profitability - Total revenue for Q3 2022 reached CNY 2,768,208,563.01, an increase of 37.31% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 20.95% to CNY 375,674,760.35 for Q3 2022[4] - Operating revenue increased to ¥7,402,793,998.96, a year-on-year growth of 39.63% compared to ¥5,301,532,904.44[8] - Total revenue for the nine months ended September 30, 2022, was RMB 7,402,794 thousand, an increase from RMB 5,301,533 thousand in the same period of 2021, representing a growth of 32.5%[46] - Net profit for the current period is 944,178,254.54, down from 1,003,928,223.19 in the previous period, indicating a decrease of approximately 5.9%[35] - The company reported a profit attributable to equity holders of RMB 961,107 thousand for the nine months ended September 30, 2022, down from RMB 1,040,063 thousand in 2021, indicating a decline of 7.6%[51] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of CNY 1,395,070,031.14 for the year-to-date period, a decrease of 1.46% compared to the previous year[4] - Cash and cash equivalents decreased by 42.36% to ¥2,042,501,533.84 from ¥3,543,819,700.44, a reduction of ¥1,501,318,200[8] - Cash inflow from operating activities is 7,076,581,251.14, an increase from 5,410,437,911.75 in the previous period, reflecting a growth of approximately 30.8%[37] - Cash outflow from investment activities is 5,208,210,770.23, down from 7,505,559,923.92 in the previous period, indicating a reduction of approximately 30.5%[42] - Cash and cash equivalents decreased to RMB 1,780,290 thousand from RMB 3,526,577 thousand at the beginning of the year, indicating a decline of 49.5%[47] Assets and Liabilities - The total assets as of the end of Q3 2022 were CNY 19,706,904,963.16, reflecting a 7.17% increase from the end of the previous year[4] - Total liabilities increased to CNY 9,165,741,734.83 from CNY 8,093,817,609.58, marking a rise of 13.2%[26] - Total non-current assets increased to RMB 13,054,092 thousand as of September 30, 2022, up from RMB 9,745,622 thousand at the beginning of the year, marking a growth of 33.7%[47] - The company’s total assets less current liabilities amounted to RMB 16,060,504 thousand, an increase from RMB 15,407,128 thousand at the beginning of the year[47] Equity and Shareholder Information - The total equity attributable to shareholders was CNY 10,401,703,789.08, a 2.69% increase from the end of the previous year[4] - The total number of common shareholders at the end of the reporting period was 34,592[18] - The top ten shareholders collectively hold significant stakes, with HKSCC NOMINEES LIMITED owning 16.88% and Shenzhen Xinchongkang Investment Partnership holding 16.79%[19] Expenses and Cost Management - Total operating costs increased by 39.81% to ¥4,701,717,656.76 from ¥3,362,990,019.03, in line with revenue growth[14] - Sales expenses increased by 56.20% to ¥163,039,241.44 compared to ¥104,381,393.02 in the same period last year[15] - Management expenses rose by 73.19% to ¥1,036,265,811.81 from ¥598,348,091.85 year-on-year, primarily due to increased personnel costs and acquisitions[15] - R&D expenses grew by 61.55% to ¥177,468,493.98, up from ¥109,851,832.35, reflecting the company's commitment to enhancing R&D capabilities[15] Profit Margins and Earnings Per Share - The basic earnings per share for Q3 2022 was CNY 0.3171, down 20.71% year-on-year[4] - The net profit excluding non-recurring gains and losses increased by 8.79% to CNY 377,837,497.51 for Q3 2022[4] - Basic earnings per share for the current period is 0.8118, down from 0.8754 in the previous period, representing a decrease of approximately 7.3%[36] Government Support and Subsidies - The company received government subsidies amounting to CNY 11,466,691.04 during the reporting period[6]